Press time:2020-12-14From:CR Pharma [ Font:BigMediumSmall]
On December 9, the innovative drug research and development platform of CR Pharm, NIP Pharm, received the "Notice of Drug Clinical Trial Approval" issued by the National Medical Products Administration (NMPA), approving NIP046 tablets for rheumatoid arthritis adaptation Clinical trials.
NIP046 is a class I small-molecule innovative drug developed by NIP Pharm. It has a clear mechanism of action and high selectivity. In non-clinical studies, it has shown excellent efficacy against a variety of autoimmune disease animal models and has good safety. In addition to rheumatoid arthritis, NIP046 also has therapeutic potential for other autoimmune diseases such as systemic lupus erythematosus, multiple sclerosis, allergic dermatitis, and corpus sores.
Following the clinical trials of the innovative drug NIP292 for the treatment of idiopathic pulmonary fibrosis in the United States, the successful clinical approval of NIP046 marks another important step taken by CR Pharm and NIP Pharm on the road of independent research and development of innovative drugs.
